Clearside Biomedical, Inc. to Report First Quarter 2017 Financial Results on May 10, 2017 – Conference Call to Follow


ALPHARETTA, Ga., May 03, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) (“Clearside” or the “Company”), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that its first quarter 2017 financial results will be released at approximately 7:00 a.m. ET on Wednesday, May 10, 2017. Following the release, Clearside will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a general business and strategic review.

The live webcast and a replay may be accessed by visiting the “Investor Relations” section at Alternately, please call (844) 263-8310 (U.S.) or (213) 358-0959 (international) to participate in the live conference call. The conference ID number for the live call is 17122858. Please dial in approximately 10 minutes prior to the call. An archive of the webcast will be available until June 10, 2017.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and pre-clinical candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration.  To learn more about how Clearside is changing ophthalmology, please visit us at



Stephen Kilmer
Investor Relations

Charles Deignan
Chief Financial Officer

footer logo


Clearside Biomedical, Inc.

Let’s get the conversation going

Questions? We’d love to hear from you.


Investor Menu